T
TScan Therapeutics D
D
TCRX
0.23180
USD
0.02
(8.17%)
مفتوح الان
آخر تحديث: · متأخرة 15 دقيقة
حجم التداول
12,133
الربح لكل سهم
-1
العائد الربحي
-
P/E
-0
حجم السوق
15,711,231
العنوان: TScan Therapeutics
القطاع: الرعاية الصحية
الصناعة: Biotechnology
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation.It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.